BR112014009528A2 - métodos e composições para tratar eritropoiese ineficaz - Google Patents

métodos e composições para tratar eritropoiese ineficaz

Info

Publication number: BR112014009528A2
Authority: BR; Brazil
Prior art keywords: compositions; methods; ineffective erythropoiesis; treating ineffective; treating
Prior art date: 2011-10-17

Application number

BR112014009528A

Other languages

English (en)

Other versions

BR112014009528A8 (pt

BR112014009528B1 (pt

Inventor

Seehra Jasbir

Venkata Sai Rajasekhar Suragani Naga

Kumar Ravindra

Scott Pearsall Robert

Original Assignee

Acceleron Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-17

Filing date

2012-10-17

Publication date

2017-05-09

2012-10-17 Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc

2012-10-17 Priority to BR122019023166-4A priority Critical patent/BR122019023166B1/pt

2012-10-17 Priority to BR122019023174-5A priority patent/BR122019023174B1/pt

2017-05-09 Publication of BR112014009528A2 publication Critical patent/BR112014009528A2/pt

2019-12-10 Publication of BR112014009528A8 publication Critical patent/BR112014009528A8/pt

2020-12-29 Publication of BR112014009528B1 publication Critical patent/BR112014009528B1/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Endocrinology (AREA)
Mycology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BR112014009528-0A 2011-10-17 2012-10-17 usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz BR112014009528B1 (pt)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
BR122019023166-4A BR122019023166B1 (pt)	2011-10-17	2012-10-17	Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à mielofibrose
BR122019023174-5A BR122019023174B1 (pt)	2011-10-17	2012-10-17	Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à esplenomegalia

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201161547932P	2011-10-17	2011-10-17
US61/547,932		2011-10-17
PCT/US2012/060650 WO2013059347A1 (en)	2011-10-17	2012-10-17	Methods and compositions for treating ineffective erythropoiesis

Publications (3)

Publication Number	Publication Date
BR112014009528A2 true BR112014009528A2 (pt)	2017-05-09
BR112014009528A8 BR112014009528A8 (pt)	2019-12-10
BR112014009528B1 BR112014009528B1 (pt)	2020-12-29

Family

ID=48141315

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
BR122019023174-5A BR122019023174B1 (pt)	2011-10-17	2012-10-17	Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à esplenomegalia
BR112014009528-0A BR112014009528B1 (pt)	2011-10-17	2012-10-17	usos de polipeptídeos actriib para a fabricação de um medicamento para tratar eritropoiese ineficaz
BR122019023166-4A BR122019023166B1 (pt)	2011-10-17	2012-10-17	Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à mielofibrose

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BR122019023174-5A BR122019023174B1 (pt)	2011-10-17	2012-10-17	Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à esplenomegalia

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
BR122019023166-4A BR122019023166B1 (pt)	2011-10-17	2012-10-17	Uso de um polipeptídeo para a fabricação de um medicamento paratratar anemia associada à mielofibrose

Country Status (13)

Country	Link
US (4)	US20130243743A1 (pt)
EP (3)	EP3875104B1 (pt)
JP (4)	JP6092883B2 (pt)
KR (4)	KR20220075438A (pt)
CN (3)	CN107837390A (pt)
AU (4)	AU2012326207B2 (pt)
BR (3)	BR122019023174B1 (pt)
CA (1)	CA2852683A1 (pt)
DK (2)	DK3520805T3 (pt)
EA (2)	EA202090053A3 (pt)
ES (3)	ES2869168T3 (pt)
HK (2)	HK1250341A1 (pt)
WO (1)	WO2013059347A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3489257A1 (en)	2004-07-23	2019-05-29	Acceleron Pharma Inc.	Actrii receptor polypeptides, methods and compositions
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
ES2839549T3 (es)	2005-11-23	2021-07-05	Acceleron Pharma Inc	Antagonistas de activina-ActRIIa de utilización en la estimulación del crecimiento óseo
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es)	2007-02-01	2009-10-12	Acceleron Pharma Inc	Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh)	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
BRPI0807506B1 (pt)	2007-02-09	2022-02-15	Acceleron Pharma, Inc	Uso de uma proteína de fusão actriia-fc para a fabricação de um medicamento para tratar ou previnir mieloma múltiplo
EP2207562B1 (en)	2007-09-18	2017-05-31	Acceleron Pharma, Inc.	Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
PL3494986T3 (pl)	2008-08-14	2020-11-16	Acceleron Pharma Inc.	Pułapki GDF
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
JP5912078B2 (ja)	2009-06-08	2016-04-27	アクセルロンファーマ，インコーポレイテッド	熱発生性脂肪細胞を増加させるための方法
JP2012529294A (ja)	2009-06-12	2012-11-22	アクセルロンファーマ，インコーポレイテッド	切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
ES2613523T3 (es) *	2009-09-09	2017-05-24	Acceleron Pharma, Inc.	Antagonistas de ActRIIb y dosificación y usos de los mismos
CA2781152A1 (en)	2009-11-17	2011-05-26	Acceleron Pharma Inc.	Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
EP2638065A4 (en)	2010-11-08	2014-04-09	Acceleron Pharma Inc	ACTRIIA-BINDING SUBSTANCES AND ITS USES
WO2013055476A1 (en)	2011-09-09	2013-04-18	Anthrogenesis Corporation	Treatment of amyotrophic lateral sclerosis using placental stem cells
NZ707477A (en)	2012-11-02	2019-09-27	Celgene Corp	Activin-actrii antagonists and uses for treating bone and other disorders
US20160046690A1 (en) *	2014-03-21	2016-02-18	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating ineffective erythropoiesis
WO2015161220A1 (en) *	2014-04-18	2015-10-22	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating sickle-cell disease
TN2016000553A1 (en)	2014-06-13	2018-04-04	Acceleron Pharma Inc	Methods and compositions for treating ulcers
MA41052A (fr)	2014-10-09	2017-08-15	Celgene Corp	Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
EP4233889A3 (en) *	2014-12-03	2023-10-11	Celgene Corporation	Activin-actrii antagonists and uses for treating myelodysplastic syndrome
MA41119A (fr) *	2014-12-03	2017-10-10	Acceleron Pharma Inc	Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
US10913782B2 (en)	2015-04-22	2021-02-09	Biogen Ma Inc.	Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases
MY189601A (en) *	2015-05-13	2022-02-18	Celgene Corp	Treatment of beta-thalassemia using actrii ligand traps
US10548976B2 (en) *	2015-05-20	2020-02-04	Celgene Corporation	In vitro cell culture methods for beta-thalassemia using activin type II receptor ligand traps
US11123430B2 (en)	2015-11-04	2021-09-21	Acceleron Pharma Inc.	Methods for increasing red blood cell levels and treating ineffective erythropoiesis
WO2017091706A1 (en)	2015-11-23	2017-06-01	Acceleron Pharma Inc.	Methods for treating eye disorders
SI3490582T1 (sl)	2016-07-27	2024-09-30	Acceleron Pharma Inc.	Sestavki za uporabo proti zdravljenju mielofibroze
US11267865B2 (en) *	2016-10-05	2022-03-08	Acceleron Pharma Inc.	Variant ActRIIB proteins and uses thereof
JOP20190085A1 (ar)	2016-10-20	2019-04-17	Biogen Ma Inc	طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
US11013785B2 (en)	2016-11-10	2021-05-25	Keros Therapeutics, Inc.	Activin receptor type IIA variants and methods of use thereof
SI3638243T1 (sl)	2017-06-14	2025-03-31	Celgene Corporation	Postopki Zdravljenja Mielofibroze In Anemije, Povezane Z Mieloproliferativno Neoplazmo
EP4428147A3 (en)	2017-11-09	2024-10-30	Keros Therapeutics, Inc.	Activin receptor type iia variants and methods of use thereof
AU2019206634B2 (en)	2018-01-12	2024-06-27	Keros Therapeutics, Inc.	Activin receptor type IIB variants and methods of use thereof
CA3098679A1 (en)	2018-05-09	2019-11-14	Keros Therapeutics, Inc.	Activin receptor type iia variants and methods of use thereof
WO2021062163A1 (en)	2019-09-27	2021-04-01	Disc Medicine, Inc.	Methods for treating myelofibrosis and related conditions
EP4121088A4 (en)	2020-03-20	2024-07-03	Keros Therapeutics, Inc.	Methods of using activin receptor type iib variants
EP4121078A4 (en)	2020-03-20	2024-08-14	Keros Therapeutics, Inc.	ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
WO2021231798A1 (en)	2020-05-13	2021-11-18	Disc Medicine, Inc.	Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
US12186370B1 (en)	2020-11-05	2025-01-07	Celgene Corporation	ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1265208A (en)	1915-09-07	1918-05-07	Edward C Kahn	Liquid-fuel burner.
WO1987005330A1 (en)	1986-03-07	1987-09-11	Michel Louis Eugene Bergh	Method for enhancing glycoprotein stability
US5080891A (en)	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en)	1989-02-03	1990-08-09	Genetics Institute, Inc.	Erythropoietin receptor
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
US5677196A (en)	1993-05-18	1997-10-14	University Of Utah Research Foundation	Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en)	1994-03-29	1996-06-11	Onyx Pharmaceuticals, Inc.	Reverse two-hybrid method
US5885574A (en)	1994-07-26	1999-03-23	Amgen Inc.	Antibodies which activate an erythropoietin receptor
US5814565A (en)	1995-02-23	1998-09-29	University Of Utah Research Foundation	Integrated optic waveguide immunosensor
DE69636866D1 (en)	1995-04-11	2007-03-15	Gen Hospital Corp	Reverse "two-hybrid"-systeme
US5807839A (en) *	1997-04-15	1998-09-15	Advanced Viral Research Corp.	Method for stimulating red blood cell production
CA2359242C (en)	1999-01-21	2009-12-08	Metamorphix, Inc.	Growth differentiation factor inhibitors and uses therefor
EP1551385A4 (en) *	2002-10-15	2008-10-22	Celgene Corp	SELECTIVE CYTOKINE INHIBITOR DRUGS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
EP3489257A1 (en)	2004-07-23	2019-05-29	Acceleron Pharma Inc.	Actrii receptor polypeptides, methods and compositions
US8067562B2 (en)	2005-11-01	2011-11-29	Amgen Inc.	Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) *	2006-12-18	2010-02-04	Acceleron Pharma Inc.	Antagonists of actriib and uses for increasing red blood cell levels
TW201803890A (zh)	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
PL3494986T3 (pl) *	2008-08-14	2020-11-16	Acceleron Pharma Inc.	Pułapki GDF
US8216997B2 (en) *	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
KR20200124322A (ko) *	2009-08-13	2020-11-02	악셀레론 파마 인코포레이티드	적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용

2012
- 2012-10-17 BR BR122019023174-5A patent/BR122019023174B1/pt active IP Right Grant
- 2012-10-17 ES ES19161424T patent/ES2869168T3/es active Active
- 2012-10-17 KR KR1020227017193A patent/KR20220075438A/ko not_active Ceased
- 2012-10-17 WO PCT/US2012/060650 patent/WO2013059347A1/en not_active Ceased
- 2012-10-17 ES ES21153891T patent/ES3010483T3/es active Active
- 2012-10-17 KR KR1020197025484A patent/KR102079482B1/ko active Active
- 2012-10-17 DK DK19161424.7T patent/DK3520805T3/da active
- 2012-10-17 US US13/654,191 patent/US20130243743A1/en not_active Abandoned
- 2012-10-17 CN CN201711069431.3A patent/CN107837390A/zh active Pending
- 2012-10-17 BR BR112014009528-0A patent/BR112014009528B1/pt active IP Right Grant
- 2012-10-17 AU AU2012326207A patent/AU2012326207B2/en active Active
- 2012-10-17 ES ES12842601T patent/ES2741477T3/es active Active
- 2012-10-17 KR KR1020207004201A patent/KR20200019261A/ko not_active Ceased
- 2012-10-17 JP JP2014537186A patent/JP6092883B2/ja active Active
- 2012-10-17 CA CA2852683A patent/CA2852683A1/en active Pending
- 2012-10-17 CN CN201280061672.2A patent/CN103987403B/zh active Active
- 2012-10-17 EP EP21153891.3A patent/EP3875104B1/en active Active
- 2012-10-17 EA EA202090053A patent/EA202090053A3/ru unknown
- 2012-10-17 EA EA201490809A patent/EA034563B1/ru not_active IP Right Cessation
- 2012-10-17 EP EP12842601.2A patent/EP2797620B1/en active Active
- 2012-10-17 EP EP19161424.7A patent/EP3520805B1/en active Active
- 2012-10-17 CN CN201711069457.8A patent/CN107693776A/zh active Pending
- 2012-10-17 KR KR1020147013325A patent/KR20140084211A/ko not_active Ceased
- 2012-10-17 DK DK21153891.3T patent/DK3875104T3/da active
- 2012-10-17 BR BR122019023166-4A patent/BR122019023166B1/pt active IP Right Grant
2017
- 2017-01-23 US US15/413,184 patent/US20170137791A1/en not_active Abandoned
- 2017-02-09 JP JP2017022176A patent/JP6383821B2/ja active Active
- 2017-03-08 AU AU2017201580A patent/AU2017201580B2/en active Active
- 2017-07-28 US US15/663,361 patent/US20170327800A1/en not_active Abandoned
2018
- 2018-07-30 HK HK18109792.1A patent/HK1250341A1/zh unknown
- 2018-08-06 JP JP2018147507A patent/JP6796626B2/ja active Active
- 2018-09-26 HK HK18112295.7A patent/HK1252940A1/zh unknown
- 2018-10-11 AU AU2018247262A patent/AU2018247262B2/en active Active
2020
- 2020-08-07 US US16/987,756 patent/US20210207107A1/en active Pending
- 2020-08-24 JP JP2020140889A patent/JP2020186277A/ja active Pending
- 2020-12-09 AU AU2020286229A patent/AU2020286229A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20190105113A (ko)	2019-09-11
ES2869168T3 (es)	2021-10-25
WO2013059347A1 (en)	2013-04-25
CA2852683A1 (en)	2013-04-25
CN107837390A (zh)	2018-03-27
EA201490809A1 (ru)	2014-09-30
EP3520805A1 (en)	2019-08-07
EA202090053A2 (ru)	2020-04-30
DK3520805T3 (da)	2021-04-19
US20170327800A1 (en)	2017-11-16
EA202090053A3 (ru)	2020-06-30
HK1252940A1 (zh)	2019-06-06
JP6796626B2 (ja)	2020-12-09
KR20220075438A (ko)	2022-06-08
ES2741477T3 (es)	2020-02-11
KR102079482B1 (ko)	2020-02-19
JP6383821B2 (ja)	2018-08-29
JP2017101060A (ja)	2017-06-08
AU2012326207A1 (en)	2014-05-15
BR122019023174B1 (pt)	2021-02-23
EP2797620B1 (en)	2019-04-24
EP2797620A1 (en)	2014-11-05
US20210207107A1 (en)	2021-07-08
AU2018247262B2 (en)	2020-12-24
DK3875104T3 (da)	2025-02-03
BR112014009528A8 (pt)	2019-12-10
AU2012326207B2 (en)	2016-12-15
EP3875104A1 (en)	2021-09-08
JP2018165287A (ja)	2018-10-25
ES3010483T3 (en)	2025-04-03
CN103987403A (zh)	2014-08-13
AU2017201580B2 (en)	2018-07-12
KR20200019261A (ko)	2020-02-21
HK1203413A1 (en)	2015-10-30
EP3520805B1 (en)	2021-03-10
EP2797620A4 (en)	2015-05-20
JP6092883B2 (ja)	2017-03-08
US20170137791A1 (en)	2017-05-18
CN103987403B (zh)	2017-12-01
JP2020186277A (ja)	2020-11-19
KR20140084211A (ko)	2014-07-04
JP2014530253A (ja)	2014-11-17
EP3875104B1 (en)	2025-01-22
BR122019023166B1 (pt)	2021-02-23
HK1250341A1 (zh)	2018-12-14
EA034563B1 (ru)	2020-02-20
BR112014009528B1 (pt)	2020-12-29
AU2018247262A1 (en)	2018-11-01
US20130243743A1 (en)	2013-09-19
CN107693776A (zh)	2018-02-16
AU2017201580A1 (en)	2017-03-30
AU2020286229A1 (en)	2021-01-07

Publication	Publication Date	Title
BR112014009528A2 (pt)	2017-05-09	métodos e composições para tratar eritropoiese ineficaz
BR112013019732A2 (pt)	2016-10-25	composições e métodos para tratamento de doenças cardiovasculares
BR112013029813A2 (pt)	2016-12-06	métodos e dispositivos para distribuição de conteúdo
PT2739268T (pt)	2019-01-28	Método e formulação para inalação
CL2015001157A1 (es)	2015-10-16	Composiciones y métodos para tratar proteinopatías.
BR112013018679A2 (pt)	2016-10-18	agente para o tratamento da alopecia
EP2780299A4 (en)	2015-04-22	FUNCTION MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
BR112013024401A2 (pt)	2017-11-07	métodos e composições para o tratamento do transtorno do déficit de atenção
BR112014014234A2 (pt)	2017-06-13	composição não colorante para tratar as fibras queratínicas e método para tratar as fibras queratínicas
BR112014013246A2 (pt)	2017-06-13	composição catalisadora, e, método para tratar nox
BR112014010450A2 (pt)	2017-04-18	composição e método
BR112014016389A2 (pt)	2017-06-13	composições e métodos para o tratamento de doenças e distúrbios hepáticos
CO6890100A2 (es)	2014-03-10	Tratamientos de combinación para hepatitis c
EP2665481A4 (en)	2014-08-06	METHOD AND COMPOSITIONS FOR TREATING METABOLIC SYNDROME
BR112013030381A2 (pt)	2017-08-08	reagentes e métodos para tratar doença dental
BR112014004414A2 (pt)	2017-03-28	composições e métodos para tratar doença neurodegenerativa
BR112015006512A2 (pt)	2017-08-08	composição para tratar tecidos biológicos danificados
EP2713715A4 (en)	2014-11-05	COMPOSITIONS AND METHODS OF TREATING MATERIALS WITH INSECTICIDES AND POTENTRICULENT AGENTS
BR112014031512A2 (pt)	2017-08-01	composição cosmética e método para o tratamento cosmético.
BR112013022306A2 (pt)	2016-12-06	método, e, composição
HUE048596T2 (hu)	2020-08-28	Eljárások és készítmények depresszió kezelésére ciklobenzaprin alkalmazásával
BR112013028890A2 (pt)	2017-01-31	composições e métodos para o tratamento de câncer
BR112013019224A2 (pt)	2016-10-11	composição, e metodo
BR112014012759A2 (pt)	2017-06-13	composto, composição e método para tratamento
BR112014010860A2 (pt)	2017-05-02	composição e método

Legal Events

Date	Code	Title	Description
2018-01-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-03-27	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-07-31	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2019-08-06	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2020-05-12	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-08-25	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-12-29	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/10/2012, OBSERVADAS AS CONDICOES LEGAIS.